Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Octreotide (DP1038) vs SC Sandostatin in Healthy Volunteers
NCT03031535Phase 1Completed
- Sponsor
- Dauntless Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DP1038 in acromegaly (6 arms), sponsored by Dauntless Pharmaceuticals. Primary endpoint: Percentage of subjects reporting adverse events (AEs)/serious adverse events (SAEs) at 1 week. Started Jan 2017; status: completed.
02
Drugs
DP1038
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT03031535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031535.